Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Transplant Recipient Clear all
Completed Phase 1 Interventional

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

NCT01165580
View directory record Official record
Conditions
Cytomegalovirus Infections, Heart Transplantation
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 124 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Withdrawn Not applicable Interventional

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

NCT01612299
View directory record Official record
Conditions
Renal Transplant
Interventions
Zortress® /Everolimus
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Not applicable Interventional

Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept

NCT00166153
View directory record Official record
Conditions
Cardiac Transplantation
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Weeks to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

HCV Positive Heart Donors

NCT03382847
View directory record Official record
Conditions
Heart Failure
Interventions
Transplant with HCV positive donor, followed by surveillance and treatment of viremia
Combination Product
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 10:24 AM EDT
Withdrawn No phase listed Observational

Severe CAV MRI in Heart Transplant Recipient

NCT02777255
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

NCT02178943
View directory record Official record
Conditions
Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
28
States / cities
Beverly Hills, California • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational

Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function

NCT02752789
View directory record Official record
Conditions
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 30, 2026, 10:24 AM EDT
Not listed No phase listed Observational

Heartsbreath Test for Heart Transplant Rejection

NCT01397812
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
BreathScanner 1.0, BreathLink
Device
Lead sponsor
Menssana Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Stanford, California • Newark, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional Results available

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

NCT01278745
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Interventions
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Recruiting Phase 4 Interventional

Randomized Trial of SGLT2i in Heart Transplant Recipients

NCT06625073
View directory record Official record
Conditions
Heart Transplant, Cardiovascular Disease, Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Palo Alto, California • Nashville, Tennessee • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Recruiting Phase 2 Interventional

Belatacept in Heart Transplantation

NCT06478017
View directory record Official record
Conditions
Heart Transplant
Interventions
Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 76 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 4 Interventional

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

NCT00121784
View directory record Official record
Conditions
Heart Transplantation
Interventions
mycophenolate mofetil [CellCept]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
11
States / cities
Chicago, Illinois • Maywood, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Withdrawn Not applicable Interventional

Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients

NCT01305395
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sirolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational

Quality of Life in Pediatric Transplant Recipients

NCT00209196
View directory record Official record
Conditions
Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Heart-Lung Transplantation
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
11 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 4 Interventional

Pharmacokinetics of Mmf and Valganciclovir

NCT00189150
View directory record Official record
Conditions
Kidney Transplant Recipient, Heart Transplant Recipient
Interventions
Mycophenolate mofetil, Valganciclovir
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Recruiting Not applicable Interventional

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

NCT06659952
View directory record Official record
Conditions
HIV Infection, Advanced End Stage Heart Failure
Interventions
HIV-positive heart transplant
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Not applicable Interventional

SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart

NCT03574012
View directory record Official record
Conditions
Acute Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Lymphoma
Interventions
Monitoring Device, Informational Intervention, Questionnaire Administration
Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Pediatric Heart Transplantation: Transitioning to Adult Care

NCT02090257
View directory record Official record
Conditions
Heart Transplantation
Interventions
TRANSIT
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Loma Linda, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

NCT05373108
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Macitentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 10:24 AM EDT
Not listed Phase 4 Interventional

Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus

NCT04917718
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Transplant
Interventions
Conversion from IR Tacrolimus to XR Tacrolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Letermovir Use in Heart Transplant Recipients

NCT04904614
View directory record Official record
Conditions
Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
Interventions
Letermovir
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 30, 2026, 10:24 AM EDT